Predict your next investment

Venture Capital
denovovc.com

See what CB Insights has to offer

Investments

157

Portfolio Exits

28

Funds

3

About De Novo Ventures

De Novo Ventures is a venture capital firm specializing in seed, startup, and emerging growth companies in the medical device and biotechnology sectors.

De Novo Ventures Headquarter Location

2180 Sand Hill Road Suite 200

Menlo Park, California, 94025,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest De Novo Ventures News

MedLumics closes upsized 18M€ financing round

Oct 28, 2021

MedLumics closes upsized 18M€ financing round    You are here MedLumics closes upsized 18M€ financing round MADRID, FEBRUARY 10th 2021 – MedLumics, a privately held medical device company developing AblaView, the first optically-guided real-time ablation catheter system for the treatment of Atrial Fibrillation (AF), announced today that it has closed an upsized EUR 18 million (USD 21.7 million) financing round and has appointed Rich Ferrari as Chairman of the Board of Directors. MedLumics’ optical catheter displays lesion creation in real-time providing the physician with direct visual confirmation of conduction tissue denaturation. Kurma Partners joined the round which includes and was initially led by Asabys Partners, along with new investors, VI Partners Swiss Innovation and CDTI Innvierte Economía, and existing investors Andera Partners, Caixa Capital Risc and Innogest Capital II. Having achieved pre-clinical feasibility in 2020, these proceeds will now enable MedLumics to initiate first in-human regulatory clinical studies and automate scalable product manufacturing. Concurrent with the financing, Medlumics welcomes renowned venture capital investor Rich Ferrari as new Chairman of the Board of Directors. Mr. Ferrari brings to the team his wealth of experience in medical device innovation and commercialization as a successful CEO of two publicly traded medical technology companies and as co-founder and Managing Director of De Novo Ventures. Current Chairman Olivier Litzka of Andera Partners will assume the role of Vice Chairman. Commenting on the news, James Greene, CEO of MedLumics, said: “We are very please to have received funding from such a strong investment syndicate and I am delighted to welcome Rich Ferrari as Chairman to our Board. We are honoured to have attracted someone of his calibre and look forward to benefiting from his impressive experience to support MedLumics as we progress through our development towards market entry. I would like to give heartfelt thanks to Olivier Litzka for his advice and guidance these past years and we are very grateful for his continued support as Vice Chairman of the Board.” Olivier Litzka, Partner at Andera Partners, commented: “We have seen an intensive and exciting period between 2017 and 2020, in which Medlumics has masterminded technically one of the most difficult to accomplish challenges in the electrophysiology lab by delivering a catheter which is capable of performing real-time lesion assessments during AF ablation. Following this achievement, we are in a favourable position to have attracted Rich Ferrari, an accomplished medtech entrepreneur, executive, board member and investor, and we look forward to moving towards clinical proof of concept under his Chairmanship.” Rich Ferrari, newly appointed Chairman, added: “I am very excited to be joining such a competent team and board of directors. The Medlumics technology has the potential to greatly enhance clinical outcomes by providing real time feedback on constant contact of the ablation and visual display of the depth and conductivity of the tissue.” Peter Neubeck, Partner at Kurma Partners, said: “We are excited to work with MedLumics in developing a truly innovative technology, a potential game changer in the interventional treatment of Atrial Fibrillation, a multi-billion-euro market opportunity. Patient outcomes will be dramatically impacted by the ability of clinicians to follow in real time the progression of ablations and their quality. We are happy to be joining this talented team and our syndicate partners, in supporting MedLumics’ evolution into a successful international business.” Atrial Fibrillation is the most common type of cardiac arrhythmia, currently affecting an estimated 33 million people worldwide. AF recurrence remains high with more than 20% of patients undergoing repeat ablation within one year of initial treatment. Addressing an unmet clinical need, AblaView is the first imaging system to directly assess lesion creation, allowing the operator to confidently ascertain the stability of the contact and the positioning of the catheter on the atrial wall. Recent preclinical studies have been successful in demonstrating reliable monitoring of the continuity and transmurality of the cardiac tissue ablation in real-time. Rich Ferrari has over 35 years in the healthcare industry, with a demonstrated history of working in the venture capital and private equity industry. Prior to founding De Novo Ventures in 2000, Rich was a successful CEO of medical technology companies, CardioThoracic Systems (CTS) and Cardiovascular Imaging Systems, both of which he took public. Rich remains very active as Executive Chairman of De Novo Ventures and mentors many first time CEOs. He also serves as a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum, as well as a board member for the Stanford Coulter Foundation for Translational Medicine. Rich holds a BS degree from Ashland University and an MBA from the University of South Florida. Posted on 10 Feb 2021  MedLumics Search Topics

De Novo Ventures Investments

157 Investments

De Novo Ventures has made 157 investments. Their latest investment was in Cormatrix Cardiovascular as part of their Private Equity on July 7, 2021.

CBI Logo

De Novo Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/28/2021

Private Equity

Cormatrix Cardiovascular

No

1

4/16/2020

Series D

RefleXion

$100M

Yes

10

7/12/2019

Series C - II

Potrero Medical

$17.19M

Yes

3

4/29/2019

Series G

Subscribe to see more

$99M

Subscribe to see more

10

5/2/2018

Unattributed VC - III

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/28/2021

4/16/2020

7/12/2019

4/29/2019

5/2/2018

Round

Private Equity

Series D

Series C - II

Series G

Unattributed VC - III

Company

Cormatrix Cardiovascular

RefleXion

Potrero Medical

Subscribe to see more

Subscribe to see more

Amount

$100M

$17.19M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

3

10

10

De Novo Ventures Portfolio Exits

28 Portfolio Exits

De Novo Ventures has 28 portfolio exits. Their latest portfolio exit was Tenon Medical on April 27, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/27/2022

IPO

$99M

Public

3

11/24/2021

IPO

$99M

Public

2

4/13/2021

Acquired

$99M

5

12/16/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

11/30/2020

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/27/2022

11/24/2021

4/13/2021

12/16/2020

11/30/2020

Exit

IPO

IPO

Acquired

Acquired

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

3

2

5

10

10

De Novo Ventures Fund History

3 Fund Histories

De Novo Ventures has 3 funds, including De Novo Ventures III LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

8/23/2006

De Novo Ventures III LP

Early-Stage Venture Capital

Closed

$300M

1

3/15/2004

De Novo Ventures II LP

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2000

De Novo Ventures LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

8/23/2006

3/15/2004

12/31/2000

Fund

De Novo Ventures III LP

De Novo Ventures II LP

De Novo Ventures LP

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Amount

$300M

$99M

$99M

Sources

1

10

10

De Novo Ventures Team

10 Team Members

De Novo Ventures has 10 team members, including current Founder, Managing Director, Richard Ferrari.

Name

Work History

Title

Status

Richard Ferrari

Founder, Managing Director

Current

David Mauney

Flagship Pioneering, Ziopharm Oncology, Harvest Capital Strategies, and Asset Management

Founder

Current

Cathy Minshall

Chief Financial Officer

Current

Fred Dotzler

Managing Director

Current

F. Thomas Watkins

Managing Director

Current

Name

Richard Ferrari

David Mauney

Cathy Minshall

Fred Dotzler

F. Thomas Watkins

Work History

Flagship Pioneering, Ziopharm Oncology, Harvest Capital Strategies, and Asset Management

Title

Founder, Managing Director

Founder

Chief Financial Officer

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.